Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Dec

Today In Oncology

Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer

Patients With HR-Positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence

Novel Targeted Therapies May Benefit Patients With Metastatic HR-Positive/HER2-Negative Breast Cancer

Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy

Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer